Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...

Biogen (NASDAQ:BIIB – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $220.00 to ...

On Monday, Biogen Inc (BIIB) stock saw a decline, ending the day at $173.52 which represents a decrease of $-0.27 or -0.16% from the prior close of $173.79. The stock opened at $173.22 and touched a ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

Market watchers, throughout the week, observed several Wall Street executives stepping up for new roles as part of leadership reshuffling. Meanwhile, some companies such as Biogen, U.S. Bancorp and ...

Biogen expects annual adjusted profit per share of $16.10 to $16.60, compared with a $15.75 to $16.25 per-share range ...

Fintel reports that on October 31, 2024, Morgan Stanley downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, ...